Medpace Holdings, Inc. Common Stock (MEDP) Q1 2022 Earnings Call Transcript

Medpace Holdings, Inc. Common Stock (MEDP -1.99%)
Q1 2022 Earnings Call
Apr 26, 2022, 9:00 a.m. ET

Contents:

• Prepared Remarks
• Questions and Answers
• Call Participants

Prepared Remarks:

Operator

Good day, ladies and gentlemen, and welcome to the Medpace first quarter 2022 earnings conference call. [Operator instructions] As a reminder, this call may be recorded. I would now like to introduce your host for today's conference call, Lauren Morris, Medpace director of investor relations. You may begin. 

Lauren Morris -- Associate Director, Investor Relations

Good morning, and thank you for joining Medpace's first quarter 2022 earnings conference call. Also on the call today is our CEO, August Troendle; our president, Jesse Geiger; and our CFO, Kevin Brady. Before we begin, I would like to remind you that our remarks and responses to your questions during this teleconference may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve inherent assumptions with known and unknown risks and uncertainties as well as other important factors that could cause actual results to differ materially from our current expectations.

These factors, including the ongoing impact of COVID-19 on our business, are discussed in our Form 10-K and other filings with the SEC. Please note that we assume no obligation to update forward-looking statements, even if estimates change. Accordingly, you should not rely on any of today's forward-looking statements as representing our views as of any date after today. During this call, we will also be referring to certain non-GAAP financial measures.

These non-GAAP measures are not superior to or replacement for the comparable GAAP measures, but we believe these measures help investors gain a more complete understanding of results. A reconciliation of such non-GAAP measures to the most directly comparable GAAP measures is available in the earnings press release and earnings call presentation slides provided in connection with today's call. The slides are available in the investor relations section of our website at investor.medpace.com. With that, I would now like to turn the call over to August Troendle.

August Troendle -- President and Chief Executive Officer

Good morning. I'm going to provide a quick update on the business environment. Softening of RFP flow observed in the first few quarters stabilized, and I'm happy to say that, overall, Q1 2022 RFPs of total volume came in roughly flat with Q1 of 2021. On the other hand, at the time of our last call, we had seen little to no evidence of funding challenges by our clients.

This has evolved. And more recently, we have seen a number of delayed or canceled programs due to funding. Looking at programs either put on hold or terminated early for lack of funds, the dollar value in the first four and a half months of 2022 has already exceeded the total for calendar year 2021. If the funding environment for our clients does not improve in the next few months, this could pose a challenge to our 2022 and 2023 growth plans.

However, at this point, we continue to anticipate 2022 revenue and profit fall within our prior guidance ranges. Earnings per share will exceed prior guidance due to share repurchases in Q1. Jesse will now provide some commentary on our results. Jesse?

Jesse Geiger -- Chief Financial Officer and Chief Operating Officer of Laboratory Operations

Thank you, and good morning, everyone. Our revenue in the first quarter of 2022 was $330.9 million, which represents a year-over-year increase of 27.3%. Net new business awards entering backlog in the first quarter increased 18.8% from the prior year to $423 million, resulting in a 1.28 net book-to-bill. And ending backlog as of March 31 was approximately $2.1 billion, an increase of 28% from the prior year.

We project that approximately $1.07 billion of backlog will convert to revenue in the next 12 months, and our backlog conversion in the first quarter was 16.6% of beginning backlog. In the first quarter, we continued to make progress in hiring, adding 4% from the end of 2021 and over 20% from the prior year. And in this challenging and competitive labor environment, employee retention and hiring for future business continues to be a top priority. With that, I will turn the call over to Kevin to review our financial performance in more detail and discuss our updated 2022 guidance.

Kevin?

Kevin Brady -- Executive Director of Finance

Thank you, Jesse, and good morning to everyone listening in. As Jesse mentioned, revenue was $330.9 million in the first quarter of 2022. This represented a year-over-year increase of 27.3% on a reported basis and 28.1% on a constant-currency organic basis. EBITDA of $70.4 million increased 31.3% compared to $53.6 million in the first quarter of 2021.

On a constant-currency basis, first quarter EBITDA increased 29.5% compared to the prior year. EBITDA margin for the first quarter was 21.3% compared to 20.6% in the prior-year period. The increased EBITDA margin was driven largely by the impact of an R&D tax credit received in the quarter. In the first quarter of 2022, net income was $61.3 million compared to net income of $43.3 million in the prior-year period.

Net income growth over the prior year was primarily driven by higher EBITDA as well as a lower effective tax rate. Net income per diluted share for the quarter was $1.69 compared to $1.14 in the prior-year period. Share repurchases during the quarter benefited EPS by $0.06. Regarding customer concentration, our top five and top 10 customers represent roughly 16% and 24%, respectively, of our first quarter revenue.

In the first quarter, we generated $46.3 million in cash flow from operating activities, and our net days sales outstanding was negative 38.7 days. During the quarter, we repurchased approximately 2.7 million shares at an average price of $155.09 for a total of $425.9 million. On March 16, 2022, our board of directors also approved an increase of $200 million to our current share repurchase program. We had $264.6 million remaining under our current share repurchase authorization at the end of the quarter.

We ended the first quarter with $82.8 million of cash, no outstanding debt and $250 million of undrawn capacity on our revolving line of credit. Moving now to our updated guidance for 2022. Full year 2022 total revenue remains unchanged in the range of $1.4 billion to $1.46 billion, representing growth of 22.6% to 27.8% over 2021 total revenue of $1.142 billion. Our 2022 EBITDA is also unchanged and expected in the range of $262 million to $278 million, representing growth of 17.4% to 24.6% compared to EBITDA of $223.1 million in 2021.

This guidance assumes a full year 2022 effective tax rate of 13.5% to 14.5% and 35.6 million fully diluted shares for 2022. There are no additional share repurchases in our guidance. We forecast 2022 net income in the range of $204 million to $216 million. Earnings per diluted share is now expected to be in the range of $5.72 to $6.06 to reflect the share repurchases in the first quarter.

With that, I will turn the call back over to the operator, so we can take your questions.

Questions & Answers:

Operator

Thank you. [Operator instructions] And our first question comes from the line of Dave Windley with Jefferies. Your line is open. Please go ahead.

Dave Windley -- Jefferies -- Analyst

Hi. Good morning. Thanks for taking my questions. August, your comments about the delayed or canceled programs that you're seeing, I'd be curious for you to elaborate there.

But maybe specifically on that, how are you handling them? I'm sure the canceled ones, you've treated as cancellations. The delays, how are you treating the delays?

August Troendle -- President and Chief Executive Officer

Sure. I mean, a delay wouldn't change its status. Some of these things are awarded, and all the revenue isn't necessarily in backlog. Our policy on backlog is pretty late, and there are stages to it.

So it's handled just as any other project of delay. Until it's a cancellation, it wouldn't be pulled out of backlog as a general policy. So it would just stay wherever it was in the pipe. Yeah.

And further detail on it, I don't know what other detail I can give. It's kind of sporadic and across the therapeutic areas. There's no like a particular focus or anything like that. And it's not highly concentrated in a single client or two.

But there's been -- it's just evidence of considerable stream in a segment of our clients.

Dave Windley -- Jefferies -- Analyst

OK. So I think one of the arguments that we hear posed is that these companies, pre-revenue biotechs that you work with a lot, are kind of exist for the purpose of developing a new drug and moving that through the pipeline. I guess, if there's no money, there's no money. But is there any perspective on their -- they have two programs, and they're canceling this one that you have to focus on the other? Or how are they canceling something that's in clinical with you I guess is what I'm trying to get at?

August Troendle -- President and Chief Executive Officer

OK. So some of them are, I guess, first off, take your question about is it generally clients with multiple products, I would say no. Generally, we're talking clients that have one main project that is their focus, and that is the project that is maybe impaired. Sometimes, there's just a restructuring of the project.

So it's delayed and maybe reorganized in terms of how they're going to execute it to try to minimize spend over a period of time. Other times, it is stopped before we get patients in the trial. So I mean, we're talking about the things, you get an award and it takes quite a while to get -- to start up. So most of these projects are not actively ongoing.

There has been some sort of restructuring of projects that are ongoing. But generally, we're talking about things that have not yet enrolled a patient and looking out at -- they didn't close the funding they hoped they were going to or looks not possible at this point. So you're right, there aren't many cancellations where it's at mid-stage and the product -- and of course, that's pretty unlikely, unless the product itself is failing. But there's a lot of overlap there in terms of the client might think it's still good enough profile, but you can get into a funding environment where -- and this hasn't happened yet, but we're -- the data isn't looking as positive as they would like in order to be able to do the raise for the remainder of the program.

So those things happen, too. But in general, we're talking about cancellations or restructuring of projects that have not entered the clinic or if they are in the clinic already are just restructuring how they're performing it.

Dave Windley -- Jefferies -- Analyst

OK. And then my last question related to this is like slower gross in new business in a quarter might be reflective or might have impact on revenue a little bit further out on the horizon. Cancellations, on the other hand, might have a little near-term impact. How should we think about the cadence of revenue through the year from here based on the updates you're giving us today?

August Troendle -- President and Chief Executive Officer

I don't really see an impact on our cadence. I don't think we've given specific guidance. And I guess, I'll turn that back to Kevin. He wants to comment on that.

But I don't think there should be a large disruption. We just wanted to signal the risks there. And I think it's -- the risks are mainly in that the funding environment continues to be bad. I mean, we think our current guidance is in place, and we can execute on those assumptions currently.

If for another six months, we continue to have the sort of funding environment we're in currently, I think that poses a real challenge for late in the year and next year. But I don't expect a big impact yet. And in terms of cadence, I don't -- Kevin, I don't know if you wanted to comment on that.

Kevin Brady -- Executive Director of Finance

Yeah. No, just to kind of reinforce what August said, we do expect in the current environment revenue to grow throughout the year, to have some sequential growth quarter over quarter. Now as you know, EBITDA for us can be very lumpy, but we do expect revenue growth throughout the year.

Dave Windley -- Jefferies -- Analyst

Great. I'll leave it at that. Thank you for the answers.

Operator

Thank you. And our next question comes from the line of Eric Coldwell with Baird. Your line is open. Please go ahead.

Eric Coldwell -- Robert W. Baird and Company -- Analyst

Thanks very much. A couple of questions here maybe in a similar vein. First off, August, you mentioned that if the delays and cancels continue for an extended period, you could see growth challenges to your growth plan in '22 and '23. But -- I'm sorry, '23 and beyond.

I'm not sure The Street is fully aware of what your growth plan is for next year. You've talked in the past about as long as the environment is a strong funding environment, you could see 20% plus growth, but we know that's not currently the case. What is your outlook for growth in '23 and maybe longer term? And I'm just seeing this in the context of The Street is already modeling about a 10-point reduction in growth for next year compared to the growth forecasted this year. I'm not sure if you're signaling that's realistic or if you think it could be below where the Street currently is.

August Troendle -- President and Chief Executive Officer

Yeah and we don't comment on future out-year growth until late in the year. We'll then try to make sure that projections by analysts, or at least they're informed by as much information as we can. But we don't really provide that for out years. We do have some internal plans, and we communicate that generally late in the year for the following year.

Eric Coldwell -- Robert W. Baird and Company -- Analyst

OK. If I could go back to the cancellation, the dollar comments on four and a half months being greater than '21. Could you give us some context of where the aggregate, either dollar volume or number of cancels were last year, where they are now? Maybe put this in historical context with any numbers, so we could get a better sense on the magnitude.

August Troendle -- President and Chief Executive Officer

Yeah. No, I don't really have a number. Our formal cancellation rates, generally 4% to 5% for opening backlog in each quarter. I don't have -- we looked back for comparative numbers because we are seeing an uptick, and really signals from clients about wanting to restructure, delay or cancel projects specifically because of funding.

They didn't close the funding or going to be unable to close funding, and that's not -- it's something we see too often and so because of that looked back at specifically those numbers and -- on the trend. And they picked up in -- through the more recent six months and has kind of really took off in the first quarter and entering second quarter of this year. So I just have -- I don't have specific numbers on those. We did look at that.

We don't want to talk about the actual dollars of that component of total cancellations, but that's what I'm referring to. And I have not signaled an overall increase in backlog cancellations beyond our 4% to 5%. And when that gets really out of range, we do comment on that also. So it's still within the usual sort of range that's in that 4% to 5% bound.

If it's substantially more than that, we would call that out also.

Eric Coldwell -- Robert W. Baird and Company -- Analyst

OK. And then I think last one for now. In the past, you've talked about the backlog lagging RFP activity. And you've said -- you've suggested obviously that it could take up to several quarters for RFPs to translate to backlog.

Is there any availability to provide a mean or a median time line, what an average or a range might be on translation of RFP activity to backlog and perhaps how that's -- if it has, how that has changed over the last year or two?

August Troendle -- President and Chief Executive Officer

Yeah. And I don't think we'd see a -- I don't know -- I haven't looked at that metric, but I don't think we'd see probably a change in the overall range meaningfully. But the range is quite broad. But I do think, sometimes, there's a misperception that these are relatively quick events.

Generally, we get RFPs, and you're not going to see any of that come into backlog in the quarter in which we see an RFP. And in fact, very little of it would get into the next quarter as -- into backlog. We see RFPs and some of them, we don't hear again for months and months, sometimes a year. Sometimes, we get and that's why I say I generally don't like looking at RFP dollars as a very strong predictor of future events.

And I've said that before because sometimes, you get into a weak environment and you see a lot of RFP requests that are kind of fundraising planning, scenario planning. And so you can actually get a tick-up in RFPs when the environment is weak. So it is a difficult measure, but we sometimes get an RFP, and then the client goes for our client group. This isn't like large pharma.

I mean, large pharma, I think, they send the RFP. They have an intent to do a program. There's generally a time frame that's relatively short over months in which they're planning on going forward with this project, and they're going to give an award. And it's going to go toward start-up.

The things can happen in the interim, and they can reprioritize. And whether it could be manufacturing problems or whatever, but it's generally pretty reliable. And our clients, a good segment of our clients, this is not very reliable. We get an RFP, and that may be -- so that they can then go back and start looking for funding, which can take years.

I mean, we could get an RFP and they go silent for a year on us and then come back. And yes, we finally closed on funding. So it is quite a while. Sometimes, they don't make a decision for a year, as I say, or more.

Sometimes it -- they give the award, but it's planned for quite a ways out. And of course, that doesn't make it into our backlog because our clients generally don't have -- or very frequently don't have the financing to do it, and that's part of the equation that they're going to solve before they get -- before they actually -- we get them to start up. So we want to see a patient ready to go into the trial before we really want to put that in backlog, and it's because we have sort of a different client group and is why. But that can be many quarters.

So the range is between a couple of quarters on the sort of low end to many, many quarters, a few years on the longer end.

Eric Coldwell -- Robert W. Baird and Company -- Analyst

OK. Thank you very much for all the details.

Operator

Thank you. [Operator instructions] And our next question comes from the line of Christine Rains with William Blair. Your line is open. Please go ahead.

Christine Rains -- William Blair and Company

Hi. Good morning. My first question is just an update on staffing overall as it relates to staff turnover and hiring. Specifically, staff growth was 24% last quarter versus 20% this quarter.

Are you moderating your hiring plans at all or do you expect an uptick as the year progresses?

Jesse Geiger -- Chief Financial Officer and Chief Operating Officer of Laboratory Operations

Yeah, I'll take that. This is Jesse. Thanks. The hiring in the first quarter was good.

We added around 4% sequentially to the headcount growth. We still do plan to hire -- try to hire at rates consistent with 2021, understanding that the first quarter was a little softer than we would have liked to keep up at that pace. But as we continue to progress through the year, we're focused on both retention and on new hires to meet continued business demand in this current environment.

Christine Rains -- William Blair and Company

Great. Thanks for that. And then my second question is how much of your enrolled patients are in China and then the same for the Ukraine and Russia? And is this disrupting your trial execution?

Jesse Geiger -- Chief Financial Officer and Chief Operating Officer of Laboratory Operations

Very small percent in both places. We're pretty well distributed across a lot of countries with the trials that we're running. We don't have any real concentration in the aggregate or in individual trials in either location.

Christine Rains -- William Blair and Company

OK, thanks. And then lastly, on the technology front, what are your clients asking for now versus a few years ago? And any specific tech areas of investment you want to highlight?

Jesse Geiger -- Chief Financial Officer and Chief Operating Officer of Laboratory Operations

Yeah. I mean, really, what's important to our client base is, from a technology standpoint, that we have the appropriate tools and technology to conduct the trials that we're involved in. And many of these tools are ones that we've had for quite some time, things like ePRO, eCOA, remote data capture, remote data review capabilities. Those are all important parts of how we conduct clinical trials.

We are always investing in technology. And I wouldn't say there's any new area to highlight other than just we're continuing to invest across the entire technology platform that we're utilizing.

Christine Rains -- William Blair and Company

OK. Thanks for the color.

Operator

Thank you. And our next question comes from the line of Paul Knight with KeyBanc. Your line is open. Please go ahead.

Paul Knight -- KeyBanc Capital Markets -- Analyst

Yeah. Thanks for the color around the stage of where your customers are delaying, I guess, is the word for it. Based on your experience of customers that are in clinical, what kind of growth do they typically step up to in terms of going from free to later stage? Is there a metric you think about in terms of growth?

August Troendle -- President and Chief Executive Officer

I guess, I'm not understanding. What do you mean by growth? The growth of their outsourcing dollars? Growth?

Paul Knight -- KeyBanc Capital Markets -- Analyst

I guess, you know what, I'm in a way digging around what 2023 could be. I know you're not guiding to it. But in terms of these customers that are in clinical trials, what would you expect their growth to be based on what you've seen customers do in the past?

August Troendle -- President and Chief Executive Officer

OK. So we don't generally look at sort of growth in specific customer dollar flow because our customer base is rather dynamic. In this industry, I've seen a lot of things drop out. So a client today has a product.

It may not succeed at all, and the revenue goes to 0 when this one study ends. And then a different client will be in the works for next year. So we kind of don't follow that metric on -- I guess, you could look at -- we could look at certainly some of our largest clients and how they go over time. But we don't really use that as a metric.

So I do think growth, we've said before, in a very strong environment that we had last year -- earlier last year was pushing growth above 20%. I think that's possible if the environment comes back. In the current environment, that's going to be challenging. It's -- there is real signs that in our -- in the substantial portion of our client base, they're challenged at closing the financing to go forward with their clinical trials.

I think that's pretty much all we can say.

Paul Knight -- KeyBanc Capital Markets -- Analyst

Yeah. And then are you able to discern whether it's -- the funding is a public equity or in VC? Is there a difference in the tone in those two markets in your view?

August Troendle -- President and Chief Executive Officer

I haven't tried to sort that out, whether the -- it's kind of a mix of privately held and public companies that have had some financing problems of late. So I think it's a mix. I haven't looked at what percentage is which. But it's both companies that are VC or privately funded at least and generally not partnered, and so privately.

So I guess, most of the VC, funded or private -- public market funding.

Paul Knight -- KeyBanc Capital Markets -- Analyst

OK, thank you.

Operator

Thank you. And I'm showing no further questions at this time. And I would like to turn the conference back over to Ms. Lauren Morris for any further remarks.

Lauren Morris -- Associate Director, Investor Relations

Thank you for joining on today's call and for your interest in Medpace. We look forward to speaking with you again on our second quarter 2022 earnings call. Thanks.

Operator

[Operator signoff]

Duration: 31 minutes

Call participants:

Lauren Morris -- Associate Director, Investor Relations

August Troendle -- President and Chief Executive Officer

Jesse Geiger -- Chief Financial Officer and Chief Operating Officer of Laboratory Operations

Kevin Brady -- Executive Director of Finance

Dave Windley -- Jefferies -- Analyst

Eric Coldwell -- Robert W. Baird and Company -- Analyst

Christine Rains -- William Blair and Company

Paul Knight -- KeyBanc Capital Markets -- Analyst

More MEDP analysis

All earnings call transcripts